Annual report
4483.TEDINET S100OD16
Period2021-04-01 → 2022-03-31
Filed2022-06-22
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 151
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥16.8bn | 2020-04-01 → 2021-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥12.2bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥10.1bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.0bn | 2017-04-01 → 2018-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.7bn | 2020-04-01 → 2021-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.4bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥596m | 2017-04-01 → 2018-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥3.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.0bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥390m | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥3.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥2.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥58.3bn | at 2021-03-31 | Cons. | Assets IFRS |
| Total assets | ¥26.9bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥19.0bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.3bn | at 2018-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.0bn | at 2021-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥13.1bn | at 2020-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥28.3bn | at 2021-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥13.1bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥6.1bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.8bn | at 2018-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥3.6bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥977m | at 2018-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.2bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.1bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥978m | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥9.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥3.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥330m | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥348m | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥18.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥4.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥1.2bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥218m | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥57.94 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥46.54 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥31.46 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥23.86 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥22.38 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥54.35 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥43.48 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥29.99 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥21.71 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥18.23 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥551.37 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥504.59 | at 2021-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥252.22 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥132.38 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥100.47 | at 2018-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.8% | at 2021-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.7% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 32.3% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 33.3% | at 2018-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 11.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.0% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 15.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 25.7% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 25.1% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 966 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 757 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 503 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 441 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 145 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥8.0bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥6.3bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥4.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.8bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥1.1bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.7bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.0bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥830m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥753m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥775m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.2bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥734m | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥534m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥387m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥577m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥41.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥42.5bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥18.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥9.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.2bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥12.1bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥14.6bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥29.3bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥27.8bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥11.4bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥5.3bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.8bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥62m | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥21.54 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.8 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.99 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.15 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.13 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥20.2 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥12.89 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.48 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥10 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥517.6 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥497.17 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥218.75 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥114.64 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥103.12 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.5% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.9% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.9% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 38.3% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 56,514,208 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 55,935,808 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 25,975,042 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,552,521 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,360 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 305 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 265 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 224 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 174 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 126 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥228m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥228m |
| Dispensing Pharmacy Supportreportable segment | employees | at 2022-03-31 | 199 pure |
| Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥3.6bn |
| Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥158m |
| Healthcare Big Datareportable segment | employees | at 2022-03-31 | 661 pure |
| Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥14.0bn |
| Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13.9bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥70m |
| Tele Medicinereportable segment | employees | at 2022-03-31 | 103 pure |
| Tele Medicinereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥4.4bn |
| Tele Medicinereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥4.4bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥22.0bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥21.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥228m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥160m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥160m |
| Dispensing Pharmacy Supportreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥2.7bn |
| Dispensing Pharmacy Supportreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥2.6bn |
| Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥128m |
| Healthcare Big Datareportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥10.2bn |
| Healthcare Big Datareportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥10.2bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥32m |
| Tele Medicinereportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥4.0bn |
| Tele Medicinereportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥4.0bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥16.9bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥16.8bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥160m |
| Healthcare Big Datareportable segment | employees | at 2022-03-31 | 305 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,603
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from short term borrowings fin cf IFRS | CurrentYearDuration | － | JPY |
| Repayments of short term borrowings fin cf IFRS | Prior1YearDuration | -840000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | CurrentYearDuration | -2622000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YearDuration | 6394000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYearDuration | 1470000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YearDuration | -645000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYearDuration | -784000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YearDuration | -514000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYearDuration | -705000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | Prior1YearDuration | 10714000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | CurrentYearDuration | － | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | Prior1YearDuration | 392000000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | CurrentYearDuration | 225000000 | JPY |
| Other fin cf IFRS | Prior1YearDuration | -15000000 | JPY |
| Other fin cf IFRS | CurrentYearDuration | 0 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YearDuration | 18107000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYearDuration | -2414000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1YearDuration | 12206000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | CurrentYearDuration | -6707000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 7692000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 19898000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YearDuration | 0 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYearDuration | 1000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 19898000000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 13192000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 10160000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 4046000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 2564000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReportableSegmentsMember | 16771000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YearDuration | 16771000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 32000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 128000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReportableSegmentsMember | 160000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReconcilingItemsMember | -160000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration | － | JPY |
| Revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 10193000000 | JPY |
| Revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 4046000000 | JPY |
| Revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 2692000000 | JPY |
| Revenue IFRS | Prior1YearDuration_ReportableSegmentsMember | 16932000000 | JPY |
| Revenue IFRS | Prior1YearDuration_ReconcilingItemsMember | -160000000 | JPY |
| Revenue IFRS | Prior1YearDuration | 16771000000 | JPY |
| Ebitda IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 3647000000 | JPY |
| Ebitda IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 1224000000 | JPY |
| Ebitda IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000DispensingPharmacySupportReportableSegmentMember | 371000000 | JPY |
| Ebitda IFRS | Prior1YearDuration_ReportableSegmentsMember | 5243000000 | JPY |
| Ebitda IFRS | Prior1YearDuration_ReconcilingItemsMember | -376000000 | JPY |
| Ebitda IFRS | Prior1YearDuration | 4867000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 825000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |